GLP-1 receptor agonists have emerged as the most effective pharmaceutical option currently available
Novo Nordisk agonist shows strong trial results as MASH cases rise among US adults For the first time, a GLP-1 therapy has been cleared to treat metabolic dysfunction-associated steatohepatitis (MASH), after the US Food and Drug Administration (FDA) granted accelerated approval to Novo Nordisks weight-loss drug Wegovy
When compared to control thresholds, which have a baseline of 1.31mIU/l or 0.4ng/ml, this increase might represent more than a 60-fold enhancement
Other Medications: Certain central nervous system medications used in GH stimulation tests, for example, dopamine agonists (like L-Dopa) or arginine, can affect GH release
Use different sites within the recommended areas (abdomen, thigh, upper arm) and maintain at least 23 cm distance from previous injection sites Ensure proper needle insertion inject at a 90-degree angle into subcutaneous tissue, not intramuscularly or intradermally Allow the medication to reach room temperature remove the pen from the refrigerator approximately 30 minutes before injection, but follow the storage instructions in the Patient Information Leaflet (PIL) and do not exceed recommended storage temperatures Clean the injection site with an alcohol wipe and allow it to dry completely before injecting Do not inject into areas with active skin conditions avoid sites with rashes, bruises, scars, or inflammation Skin preparation and aftercare: Maintain good skin hydration regular use of emollients can improve skin barrier function and potentially reduce irritation Avoid tight clothing over fresh injection sites for several hours Do not massage the injection site immediately after administration, as this may increase local irritation Patient education and monitoring: Keep a symptom diary noting injection sites, any reactions, and their duration Report persistent or worsening reactions to your healthcare provider promptly Ensure you have received proper training in injection technique from a healthcare professional Be aware of the signs of serious allergic reactions and have an action plan If you have previously experienced a serious hypersensitivity reaction to semaglutide, you should not be re-exposed to the medication
)
